Abstract
Summary
Low levels of serum properdin were found in patients with advanced cancer whose ability to reject cancer cell homografts was defective. Normal properdin levels were observed in normal persons who rejected cancer cell homografts promptly. Investigation of cellular and humoral defense mechanisms other than properdin has thus far revealed no differences which might explain the impaired rejection of implanted cells by the cancer patients.
Get full access to this article
View all access options for this article.